- Previous Close
1.5000 - Open
1.6700 - Bid 0.9465 x 100
- Ask 1.0300 x 100
- Day's Range
0.9500 - 1.7415 - 52 Week Range
0.9500 - 15.8000 - Volume
566,154 - Avg. Volume
69,557 - Market Cap (intraday)
46.397M - Beta (5Y Monthly) 0.37
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.
aspirebiolabs.comRecent News: ASBP
View MorePerformance Overview: ASBP
Trailing total returns as of 3/3/2025, which may include dividends or other distributions. Benchmark is S&P 500 .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ASBP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ASBP
View MoreValuation Measures
Market Cap
68.81M
Enterprise Value
69.65M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-648.16k
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
16.54k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--